Cholangiocarcinoma
Conditions
Interventions
Trial Arm:Icaritin in combination with gemcitabine and S-1
Sponsors
The Second Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Contrast-enhanced CT or MRCP confirmed the presence of biliary stricture, which was pathologically confirmed to be malignant or was supported by clinical evidence of malignant obstruction caused by cholangiocarcinoma; 2. Age range from 18 to 80 years old, both male and female; 3. After biliary stent placement, biliary angiography proved that the biliary tract was unobstructed; 4. The general condition was good, and the Karnofsy score within 1 week before enrollment was =60 points; 5. ECOG score =2; 6. The patients signed an informed consent form agreeing to participate in the study and were guaranteed follow-up visits.
Exclusion criteria
Exclusion criteria: 1. Combined with severe cardiopulmonary dysfunction, unable to tolerate biliary stent surgery; 2. Combined with other malignant tumors other than biliary stricture; 3. The biliary tract was not unobstructed by cholangiography at 1 week after biliary stent placement; 4. ECOG score =3; 5. Distant metastasis; 6. Patients with mental disorders; 7. Icaritin drug intolerance; 8. People who are participating in clinical trials of other drugs or receiving other treatments; 9. Other reasons were considered by the investigators to be inappropriate for clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time of biliary restenosis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Time to deterioration of quality of life; | — |
Countries
China
Contacts
Public ContactYuliang Li
The Second Hospital of Shandong University
Outcome results
None listed